Technological Advances in Tumor-On-Chip Technology: From Bench to Bedside

Bērziņa, Santa; Harrison, Alexandra; Taly, Valérie; Xiao, Wenjin

doi:10.3390/cancers13164192

Cited by 15 publications

(10 citation statements)

References 103 publications

(182 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To partially overcome this limitation, the exploitation of 3D vascularized tumor spheroid-on-chip models could be an option. These models designate a microfluidic spheroid model, which moderately reflects the 3D architecture of the tumor, tumor heterogeneity, and microenvironment [ 111 , 112 , 113 ]. Unlike spheroids on their own, they are able to mimic the dynamic properties of the tumor microenvironment, for example, by ensuring the constant perfusion of cell medium (or any other relevant biological fluids) to supply nutrients, US contrast agents (e.g., MBs, nanobubbles, nanodroplets, etc.…”

Section: Future Perspectives and Conclusionmentioning

confidence: 99%

Tumor Spheroids as Model to Design Acoustically Mediated Drug Therapies: A Review

et al. 2023

View full text Add to dashboard Cite

Tumor spheroids as well as multicellular tumor spheroids (MCTSs) are promising 3D in vitro tumor models for drug screening, drug design, drug targeting, drug toxicity, and validation of drug delivery methods. These models partly reflect the tridimensional architecture of tumors, their heterogeneity and their microenvironment, which can alter the intratumoral biodistribution, pharmacokinetics, and pharmacodynamics of drugs. The present review first focuses on current spheroid formation methods and then on in vitro investigations exploiting spheroids and MCTS for designing and validating acoustically mediated drug therapies. We discuss the limitations of the current studies and future perspectives. Various spheroid formation methods enable the easy and reproducible generation of spheroids and MCTSs. The development and assessment of acoustically mediated drug therapies have been mainly demonstrated in spheroids made up of tumor cells only. Despite the promising results obtained with these spheroids, the successful evaluation of these therapies will need to be addressed in more relevant 3D vascular MCTS models using MCTS-on-chip platforms. These MTCSs will be generated from patient-derived cancer cells and nontumor cells, such as fibroblasts, adipocytes, and immune cells.

show abstract

Section: Future Perspectives and Conclusionmentioning

confidence: 99%

Tumor Spheroids as Model to Design Acoustically Mediated Drug Therapies: A Review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The ECM has been found to simulate the development of cancer cells in vitro; hence, their interaction plays an important role in TME. Synthetic scaffold-based culture methods are widely used to recreate the ECM on chip as they closely resemble natural ECM [ 116 ]. Rijal et al [ 63 ] developed a reconstitute tissue matrix scaffold system which was fabricated using native tissue ECM whose structural and compositional feature promote cell survival, proliferation, migration, and invasion in culture along with vascularized tumors.…”

Section: Microfluidic Device In Anti-cancer Drug Screeningmentioning

confidence: 99%

Applications of Microfluidics and Organ-on-a-Chip in Cancer Research

et al. 2022

View full text Add to dashboard Cite

Taking the life of nearly 10 million people annually, cancer has become one of the major causes of mortality worldwide and a hot topic for researchers to find innovative approaches to demystify the disease and drug development. Having its root lying in microelectronics, microfluidics seems to hold great potential to explore our limited knowledge in the field of oncology. It offers numerous advantages such as a low sample volume, minimal cost, parallelization, and portability and has been advanced in the field of molecular biology and chemical synthesis. The platform has been proved to be valuable in cancer research, especially for diagnostics and prognosis purposes and has been successfully employed in recent years. Organ-on-a-chip, a biomimetic microfluidic platform, simulating the complexity of a human organ, has emerged as a breakthrough in cancer research as it provides a dynamic platform to simulate tumor growth and progression in a chip. This paper aims at giving an overview of microfluidics and organ-on-a-chip technology incorporating their historical development, physics of fluid flow and application in oncology. The current applications of microfluidics and organ-on-a-chip in the field of cancer research have been copiously discussed integrating the major application areas such as the isolation of CTCs, studying the cancer cell phenotype as well as metastasis, replicating TME in organ-on-a-chip and drug development. This technology’s significance and limitations are also addressed, giving readers a comprehensive picture of the ability of the microfluidic platform to advance the field of oncology.

show abstract

“…Patient-derived tissue biopsies preserve key cellular heterogeneity and geometry of the tumor, which are important variables for drug screenings. However, the use of tissue/tumor biopsies for microfluidic platforms is hampered by the technical challenge of on-chip imaging and off-chip analysis ( 104 ). Milliscale tissues as tumor biopsies usually give raise to culture challenge concerning the complex tissue preservation during long-term culture times ( 105 ).…”

Section: Future Prospectsmentioning

confidence: 99%

“…Other advances in microfluidic technology, such as dismantable/open and droplet-based formats, also facilitate the development of tumor-on-a-chip devices ( 104 ) ( Figure 7 ). The dismantable/open-layer feature of microfluidic platforms allows for the direct retrieval of the analyzed samples by taking apart the top layer of the device ( 104 ). Cultured materials can then be easily accessible for off-chip analysis as the histological staining of biopsies and biopsy-like tissues.…”

Section: Future Prospectsmentioning

confidence: 99%

In vitro models for head and neck cancer: Current status and future perspective

et al. 2022

View full text Add to dashboard Cite

The 5-year overall survival rate remains approximately 50% for head and neck (H&N) cancer patients, even though new cancer drugs have been approved for clinical use since 2016. Cancer drug studies are now moving toward the use of three-dimensional culture models for better emulating the unique tumor microenvironment (TME) and better predicting in vivo response to cancer treatments. Distinctive TME features, such as tumor geometry, heterogenous cellularity, and hypoxic cues, notably affect tissue aggressiveness and drug resistance. However, these features have not been fully incorporated into in vitro H&N cancer models. This review paper aims to provide a scholarly assessment of the designs, contributions, and limitations of in vitro models in H&N cancer drug research. We first review the TME features of H&N cancer that are most relevant to in vitro drug evaluation. We then evaluate a selection of advanced culture models, namely, spheroids, organotypic models, and microfluidic chips, in their applications for H&N cancer drug research. Lastly, we propose future opportunities of in vitro H&N cancer research in the prospects of high-throughput drug screening and patient-specific drug evaluation.

show abstract

Technological Advances in Tumor-On-Chip Technology: From Bench to Bedside

Cited by 15 publications

References 103 publications

Tumor Spheroids as Model to Design Acoustically Mediated Drug Therapies: A Review

Tumor Spheroids as Model to Design Acoustically Mediated Drug Therapies: A Review

Applications of Microfluidics and Organ-on-a-Chip in Cancer Research

In vitro models for head and neck cancer: Current status and future perspective

Contact Info

Product

Resources

About